EU/3/14/1301: Orphan designation for the treatment of idiopathic pulmonary fibrosis

Humanised anti-alpha ν beta 6 monoclonal antibody


On 29 July 2014, orphan designation (EU/3/14/1301) was granted by the European Commission to Biogen Idec Ltd, United Kingdom, for humanised anti-alpha ν beta 6 monoclonal antibody for the treatment of idiopathic pulmonary fibrosis.


Key facts

Active substance
Humanised anti-alpha ν beta 6 monoclonal antibody
Intended use
Treatment of idiopathic pulmonary fibrosis
Orphan designation status
EU designation number
Date of designation

Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands
Tel. + 31 20 542 2140

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

May 2019The sponsorship was transferred to Biogen Netherlands B.V., Netherlands. 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating